| INTRODUCTION
Type 2 diabetes (T2DM), once thought of as a condition of adulthood, is an emerging disease in childhood and adolescence. Globally, the highest incidence of T2DM in youth is in the United States, with 12.5 cases per 100 000 per year. 1 Recently, we reported the 2015-2016
UK incidence of T2DM in youth as 0.72 per 100 000 per year, with significant increases across a decade among South-Asians and females. 2 Our study, demonstrated that non-white ethnicity, female gender, family history, and obesity were strongly associated with disease similar to reports from other countries.
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T2DM in youth has an aggressive clinical course (compared with the disease in adults) as it is associated with an accelerated loss of Bcells and rapid development of diabetes-related complications. 4, 5 Diabetes-related complications are more common in children with T2DM compared to type 1 diabetes (T1DM). A study from Australia demonstrated higher rates of nephropathy (28% vs 6%) and hypertension (36% vs 16%) in those with T2DM compared to those with T1DM despite a shorter duration of disease. 6 A large observational study from the United States, with over 2000 children and adolescents, demonstrated higher odds of nephropathy, retinopathy, and peripheral neuropathy in those with T2DM compared to those with T1DM. 7 The trend of a higher prevalence of T2DM in youth and the rapid development of diabetes-related complications in this population is worrying for the decades ahead. Therefore, prevention, early detection in "at risk" populations and effective treatment strategies are crucial to tackle this disease.
The current guidance from International Society for Pediatric and Adolescent Diabetes (ISPAD) recommends lifestyle changes should be advised at diagnosis and first line treatment with metformin and insulin either alone or in combination. 8 In the previous 2005 cohort of children with T2DM, 94% of cases were commenced on some combination of insulin, metformin, and/or lifestyle changes. 9 Challenges to improving outcomes in T2DM in youth are numerous. Much of the evidence for management of T2DM is from adult experience. Clinicians need to be cognizant of licensing restrictions and the paucity of evidence and experience in drug usage in children. T1DM cases are evenly distributed across socioeconomic groups; however this is not the case with T2DM in youth; in the United States and Europe cases come from predominantly lower socioeconomic and educational backgrounds. 10 Treatment adherence and lack of engagement with diabetes services are key barriers to effective care. One study in Japan reported over 50% of cases of T2DM among youth was lost to follow up.
11
The purpose of this study is to report on clinical outcomes from a national cohort of children and young people with T2DM 1-year on from diagnosis.
| METHODS
A prospective monthly surveillance of over 3400 consultant pediatri- 
| Statistical analysis
HbA1c, BMI SDS, BMI SDS change at 1 year, and weight change were not normally distributed and thus non-parametric tests were used and median and interquartile range (IQR) reported to summarize data dis- ).
The association of BMI SDS with ethnic groups was examined by using multiple linear regression model adjusted for potential confounding variables including number of clinic appointments attended, clinician reported compliance concerns, and formal social involvement.
Multiple linear regression analysis was used to investigate associations between HbA1c (outcome) and potential risk factors (predictors) including age, gender, ethnicity, social care involvement, compliance, and attendance concerns reported, number of clinic appointments attended, BMI SDS, and BMI SDS change over 1 year.
Because the HbA1c was not normally distributed, the log10 trans- 3 | RESULTS
| The cohort
There were 106 cases of T2DM between April 2015 and April 2016.
One hundred follow-up questionnaires were received from notifying clinicians giving a response of 94% (see Figure 1. ). Five cases were completely lost to follow up (i.e., no clinic appointment attended since diagnosis) and therefore the notifying clinician could not report any ongoing clinical details. One case was reclassified as diabetes related to bone marrow transplantation. Therefore, at follow-up, 94 cases of T2DM were available for review.
| Patient characteristics
The mean age at follow-up was 15.3 years (range 9.3-18.4 years).
Sixty-seven per cent were female. Ethnic breakdown was white (45%), mixed ethnicity (4%), Asian (33%), Black, African, Caribbean or Black British (BACBB) (14%), Unknown (3%), and other (1%).
| Patient outcomes
The median (IQR) weight change over the year was +2.5 kg (−1.5 to There is strong evidence that there was a difference between those with and those without reported compliance and attendance concerns (61.5 vs 45.5 mmol/mol respectively, P < 0.0001).
Results demonstrated that compliance or attendance concerns (β coefficient = 0.12, P = <0.0001) and BMI SDS change at 1 year (β coefficient = 0.13, P = 0.007) were associated with HbA1c when adjusted for sex, age, ethnicity, child protection concerns, clinic appointments attended, and current BMI SDS (see Table 1 .). Clinician reported compliance or attendance concerns were associated with a 32.1% higher HbA1c compared to those without these concerns.
One-unit increase in BMI SDS was associated with 34.9% increase in HbA1c.
| Treatment
The most common treatment at diagnosis and at 1-year was metformin. Metformin was used as a monotherapy in 54/105 (51.4%) at diagnosis and 59/94 (62.8%) at 1-year (see Table 2 ), although 77% used metformin within their treatment regime at diagnosis and 87% at follow-up. The median (IQR) daily dose of metformin at follow-up was calculate, the dose range was 0.2 to 0.8 units/kg/day. Fourteen were using once daily long acting insulin, 6 were on basal-bolus regimens and 1 case on twice daily mixed insulin. As might be expected, those treated with insulin had a higher HbA1c (60 vs 44 mmol/mol, P = 0.017).
Glucagon-like peptide 1 (GLP-1) agonists were not used at diagnosis but four cases were using them at follow-up (3 liraglutide dose range 1.2-1.8 mg daily, 1 dulaglutide 1.5 mg weekly). No cases were given sulfonlyureas either at diagnosis or at follow-up.
Of those with an HbA1c below 39 mmol/mol, management included; diet and lifestyle alone (n = 4), metformin (n = 9), and metformin and insulin (n = 1).
| Comorbidity
The comorbidities reported at baseline and at follow-up are shown in Table 3 
| DISCUSSION
Young people with T2DM are at significant risk of diabetes-related complications and therefore early engagement, treatment, and achieving optimal glycemic control are crucial to achieve better long term clinical outcomes. The key messages from our study are that adherence to treatment and a reduction in BMI is strongly associated with a lower HbA1c. This can be a reassuring and simple message to young people with T2DM; adhere to treatment and you will see an improvement in your HbA1c and help reduce long term complications. Furthermore, reducing your BMI should remain the key target and is associated with improved glucose control. Greater BMI loss (0.33 BMI SDS) was attained by those with an HbA1c in "normal euglycemic" range (<39 mmol/mol) and for each one-unit increase in BMI SD score the HbA1c increases by over a third suggesting that weight reduction strategies are important to restore normal glycemic parameters. This is similar to recommendations that a reduction in BMI SDS score by more than 0.5 SDs, is likely to reflect an actual reduction in percentage fat mass. 23 In 2005, the BPSU conducted a survey of type 2 diabetes in the UK children 9,24 using the same methodology as this study DiRECT trial on the utility of low calorie diets after diagnosis. 25 Weight loss was demonstrated in the TODAY cohort, to be associated with better cardiometabolic outcomes including HbA1c, 26 though interestingly there was no effect from intensive lifestyle interventions on weight-related outcomes. 27 Over half of those diagnosed with T2DM had adherence concerns at 1-year follow-up, and on average those with T2DM are not attending a quarter of appointments offered. It is a worry that 5% of cases did not attend any follow-up after diagnosis, though significant loss to follow up has been described previously. 11 Although a previous study has shown that clinic attendance and HbA1c are associated, 28 we did not demonstrate this association in our study when we Therefore, creativity in approach, better training for diabetes teams, and adolescent accessible services must be championed for this subset of patients. In those with T2DM, a lower HbA1c has been reported by involving peer-to-peer support 30 and community health workers 31 in diabetes management. T2DM in children has been described as a disease of poverty, 32 in addition to this a disproportionate number of our cohort had active child protection interventions in place. Therefore, close liaison with social care teams is essential to support these children and their families in managing all aspects of the disease and its impact on the family. Positive experiences have been reported in having a social worker part of the team working with young people with T2DM. 33 The median HbA1c was higher in 2015 compared to 2005 (53 vs 48 mmol/mol); although a modest increase, it reflects a HbA1c above the target range for this cohort. 34 Our study showed no significant gender disparity with regard to HbA1c, though there was a trend for higher HbA1c in boys in the multiple regression model (see Table 1 , β = 0.05, P = 0.11). At a population level, in non-diabetic adolescents, HbA1c has been reported to be higher in boys than girls. 35 A recent study from the United Kingdom demonstrated higher HbA1c among young adult males with T2DM compared to females. 36 Furthermore, we did not demonstrate that ethnicity was associated with HbA1c. This is not consistent with studies from the United States, for example the SEARCH 37 study reported higher HbA1c among non-white ethnic groups.
In terms of treatment, the majority are following the IPSAD guidance on initial treatment with metformin and/or insulin. Insulin was often started at diagnosis when the patient was either not metabolically stable (or when the diagnosis of T2DM was not confirmed).
There agonists were only just being introduced into adult T2DM care, however in 2015 4% of our cohort were reportedly on these drugs. In adults, GLP-1 agonists (e.g., liraglutide) have shown to be efficacious and safe in reducing HbA1c (compared to placebo) with fewer episodes of hypoglycemia compared to sulfonylurea (glimepiride). 38 In children, the experience of using GLP-1 agonists is limited. However, studies have shown it safe and effective compared to placebo in a pediatric population. 39 The rise in cases of microalbuminuria is concerning with a 4-fold increase over 1 year. Those with microalbuminuria had higher HbA1c levels, suggesting early-onset nephropathy may associate with poorer early diabetes control. A recent paper from Scandinavia, sub-dividing T2DM into five clusters did identify that cluster 3 (Severe Insulin
Resistant Diabetes [SIRD]) associated more with accelerated kidney disease and this group may be over-represented in our cohort providing an alternate basis for the rapid increase in prevalence as insulin resistance appears intimately linked to kidney damage. 40, 41 The rapid development of microalbuminuria has been documented previously with one study demonstrating 6.3% prevalence of microalbuminuria at baseline (median disease duration of 7 months) and 16.6% by 36 months. 42 It is worrying that 28% of cases had no screen for microalbuminuria reported. Interestingly, prevalence of hypertension (21%-14%) and dyslipidemia (9%-1%) fell over the year and may reflect an improvement in overall cardiometabolic health with treatment for T2DM.
The study relies on the accuracy and objectivity of clinician responses. The clinician reported concerns about compliance with treatment cannot be quantified (as clinic attendance can be) and to do this would require more intensive assessment of the patient's compliance to medication. This is beyond the scope of our study methodology but warrants further investigation in future studies. It is interesting that clinic attendance (which was measured) was not associated with HbA1c, suggesting that engagement and adherence to management plans is more complex than just turning up for appointments. Only 6 (6%) cases of 106 at baseline failed to return a completed questionnaire. In the 2005 follow-up study the figure was 4%.
T2DM diagnosed in childhood provides a management challenge for clinicians. With the continued rise in cases in this population and the aggressive nature of the disease, it is essential that we learn how best to engage with these children and their families to ensure we have better outcomes in the next 10 years.
